Healthcare/Neuroscience Analysts, along with Dr. Anton Porsteinsson, in conjunction with Needham’s Virtual Neuroscience Forum and provide a commercial update of BIIB‘s Leqembi, discuss the upcoming TRAILBLAZER-ALZ 2 data readout for LLY‘s donanemab on an Analyst/Industry conference call to be held on March 15 at 12:15 pm.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BIIB:
- Biogen Appoints Chuck Triano as Head of Investor Relations
- Biogen appoints Triano as Head of Investor Relations
- Biogen ‘welcomes’ VHA recent decision to provide coverage to Leqembi
- VA to widely cover new Alzheimer’s treatment from Eisai and Biogen, STAT says
- Biogen price target raised to $350 from $335 at RBC Capital